|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhao D, Zhang Y and Song L: MiR-16-1
targeted silences far upstream element binding protein 1 to advance
the chemosensitivity to adriamycin in gastric cancer. Pathol Oncol
Res. 24:483–488. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sugano K: Screening of gastric cancer in
Asia. Best Pract Res Clin Gastroenterol. 29:895–905. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wei Z, Liang L, Junsong L, Rui C, Shuai C,
Guanglin Q, Shicai H, Zexing W, Jin W, Xiangming C, et al: The
impact of insulin on chemotherapeutic sensitivity to 5-fluorouracil
in gastric cancer cell lines SGC7901, MKN45 and MKN28. J Exp Clin
Cancer Res. 34:642015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Correia AL and Bissell MJ: The tumor
microenvironment is a dominant force in multidrug resistance. Drug
Resist Updat. 15:39–49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tredan O, Galmarini CM, Patel K and
Tannock IF: Drug resistance and the solid tumor microenvironment. J
Natl Cancer Inst. 99:1441–1454. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kerbel RS, St Croix B, Florenes VA and Rak
J: Induction and reversal of cell adhesion-dependent multicellular
drug resistance in solid breast tumors. Hum Cell. 9:257–264.
1996.PubMed/NCBI
|
|
8
|
Teicher BA, Herman TS, Holden SA, Wang YY,
Pfeffer MR, Crawford JW and Frei E III: Tumor resistance to
alkylating agents conferred by mechanisms operative only in vivo.
Science. 247:1457–1461. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Junttila MR and de Sauvage FJ: Influence
of tumour micro-environment heterogeneity on therapeutic response.
Nature. 501:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu CF, Huang YY, Wang YJ and Gao FG:
Upregulation of ABCG2 via the PI3K-Akt pathway contributes to
acidic microenvironment-induced cisplatin resistance in A549 and
LTEP-a-2 lung cancer cells. Oncol Rep. 36:455–461. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lowe JM, Menendez D, Bushel PR, Shatz M,
Kirk EL, Troester MA, Garantziotis S, Fessler MB and Resnick MA:
p53 and NF-kB coregulate proinflammatory gene responses in human
macrophages. Cancer Res. 74:2182–2192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
O'Reilly S, Ciechomska M, Cant R and van
Laar JM: Interleukin-6 (IL-6) trans signaling drives a
STAT3-dependent pathway that leads to hyperactive transforming
growth factor-beta (TGF-beta) signaling promoting SMAD3 activation
and fibrosis via Gremlin protein. J Biol Chem. 289:9952–9960. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Greijer AE, de Jong MC, Scheffer GL,
Shvarts A, van Diest PJ and van der Wall E: Hypoxia-induced
acidification causes mitoxantrone resistance not mediated by drug
transporters in human breast cancer cells. Cell Oncol. 27:43–49.
2005.PubMed/NCBI
|
|
14
|
Lathers DM and Young MR: Increased
aberrance of cytokine expression in plasma of patients with more
advanced squamous cell carcinoma of the head and neck. Cytokine.
25:220–228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Desai S, Kumar A, Laskar S and Pandey BN:
Cytokine profile of conditioned medium from human tumor cell lines
after acute and fractionated doses of gamma radiation and its
effect on survival of bystander tumor cells. Cytokine. 61:54–62.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yan HQ, Huang XB, Ke SZ, Jiang YN, Zhang
YH, Wang YN, Li J and Gao FG: Interleukin 6 augments lung cancer
chemotherapeutic resistance via ataxia-telangiectasia
mutated/NF-kappaB pathway activation. Cancer Sci. 105:1220–1227.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Penson RT, Kronish K, Duan Z, Feller AJ,
Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, et al:
Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in
patients with epithelial ovarian cancer and their relationship to
treatment with paclitaxel. Int J Gynecol Cancer. 10:33–41. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng GM and To KK: Adverse cell culture
conditions mimicking the tumor microenvironment upregulate ABCG2 to
mediate multidrug resistance and a more malignant phenotype. ISRN
Oncol. 2012:7460252012.PubMed/NCBI
|
|
19
|
Desai S, Laskar S and Pandey BN: Autocrine
IL-8 and VEGF mediate epithelial-mesenchymal transition and
invasiveness via p38/JNK-ATF-2 signalling in A549 lung cancer
cells. Cell Signal. 25:1780–1791. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Spanswick VJ, Lowe HL, Newton C, Bingham
JP, Bagnobianchi A, Kiakos K, Craddock C, Ledermann JA, Hochhauser
D and Hartley JA: Evidence for different mechanisms of ‘unhooking’
for melphalan and cisplatin-induced DNA interstrand cross-links in
vitro and in clinical acquired resistant tumour samples. BMC
Cancer. 12:4362012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gaudio E, Spizzo R, Paduano F, Luo Z,
Efanov A, Palamarchuk A, Leber AS, Kaou M, Zanesi N, Bottoni A, et
al: Tcl1 interacts with Atm and enhances NF-κB activation in
hematologic malignancies. Blood. 119:180–187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Svirnovski AI, Serhiyenka TF, Kustanovich
AM, Khlebko PV, Fedosenko VV, Taras IB and Bakun AV: DNA-PK, ATM
and MDR proteins inhibitors in overcoming fludarabine resistance in
CLL cells. Exp Oncol. 32:258–262. 2010.PubMed/NCBI
|
|
23
|
Wu ZH and Miyamoto S: Induction of a
pro-apoptotic ATM-NF-kappaB pathway and its repression by ATR in
response to replication stress. EMBO J. 27:1963–1973. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shiloh Y and Ziv Y: The ATM protein
kinase: Regulating the cellular response to genotoxic stress, and
more. Nat Rev Mol Cell Biol. 14:197–210. 2013. View Article : Google Scholar
|
|
25
|
Yang Y, Xia F, Hermance N, Simonson S,
Morrissey S, Gandhi P, Munson M, Miyamoto S and Kelliher MA: A
cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the
NF-kappaB and p38 mitogen-activated protein kinase
(MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol Cell
Biol. 31:2774–2786. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hayden MS and Ghosh S: Shared principles
in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ke SZ, Ni XY, Zhang YH, Wang YN, Wu B and
Gao FG: Camptothecin and cisplatin upregulate ABCG2 and MRP2
expression by activating the ATM/NF-kappaB pathway in lung cancer
cells. Int J Oncol. 42:1289–1296. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li F and Sethi G: Targeting transcription
factor NF-kappaB to overcome chemoresistance and radioresistance in
cancer therapy. Biochim Biophys Acta. 1805:167–180. 2010.PubMed/NCBI
|
|
29
|
Straussman R, Morikawa T, Shee K,
Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J,
Frederick DT, et al: Tumour micro-environment elicits innate
resistance to RAF inhibitors through HGF secretion. Nature.
487:500–504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ning Y, Manegold PC, Hong YK, Zhang W,
Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, et al:
Interleukin-8 is associated with proliferation, migration,
angiogenesis and chemosensitivity in vitro and in vivo in colon
cancer cell line models. Int J Cancer. 128:2038–2049. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rohwer N, Dame C, Haugstetter A,
Wiedenmann B, Detjen K, Schmitt CA and Cramer T: Hypoxia-inducible
factor 1alpha determines gastric cancer chemosensitivity via
modulation of p53 and NF-kappaB. PLoS One. 5:e120382010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu X, Shen H, Yin X, Long L, Chen X, Feng
F, Liu Y, Zhao P, Xu Y, Li M, et al: IL-6R/STAT3/miR-204 feedback
loop contributes to cisplatin resistance of epithelial ovarian
cancer cells. Oncotarget. 8:39154–39166. 2017.PubMed/NCBI
|
|
33
|
Hazelbag S, Fleuren GJ, Baelde JJ,
Schuuring E, Kenter GG and Gorter A: Cytokine profile of cervical
cancer cells. Gynecol Oncol. 83:235–243. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mattei S, Colombo MP, Melani C, Silvani A,
Parmiani G and Herlyn M: Expression of cytokine/growth factors and
their receptors in human melanoma and melanocytes. Int J Cancer.
56:853–857. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Burke F, Relf M, Negus R and Balkwill F: A
cytokine profile of normal and malignant ovary. Cytokine.
8:578–585. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hoesel B and Schmid JA: The complexity of
NF-κB signaling in inflammation and cancer. Mol Cancer. 12:862013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hill AA, Anderson-Baucum EK, Kennedy AJ,
Webb CD, Yull FE and Hasty AH: Activation of NF-κB drives the
enhanced survival of adipose tissue macrophages in an obesogenic
environment. Mol Metab. 4:665–677. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen ZS and Tiwari AK: Multidrug
resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic
diseases. FEBS J. 278:3226–3245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Doyle L and Ross DD: Multidrug resistance
mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene. 22:7340–7358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Candeil L, Gourdier I, Peyron D, Vezzio N,
Copois V, Bibeau F, Orsetti B, Scheffer GL, Ychou M, Khan QA, et
al: ABCG2 overexpression in colon cancer cells resistant to SN38
and in irinotecan-treated metastases. Int J Cancer. 109:848–854.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yamasaki M, Makino T, Masuzawa T, Kurokawa
Y, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Matsuura N, Mori
M, et al: Role of multidrug resistance protein 2 (MRP2) in
chemoresistance and clinical outcome in oesophageal squamous cell
carcinoma. Br J Cancer. 104:707–713. 2011. View Article : Google Scholar : PubMed/NCBI
|
